Study ID,Study,Experiment Name,Experiment Notes,Strain Ont ID,Strain,Sex,Age,# of Animals,Sample Notes,Clinical Measurement Ont ID,Phenotype,Formula,Clinical Measurement Notes,Average Type,Value,Units,SEM,SD,Method Ont ID,Method,Method Site,Method Duration,Method Notes,Post Insult Type,Post Insult Time Value,Post Insult Time Unit,Conditions,Record ID,Condition 1a,Condition 1b,Condition 1c,Condition 2a,Condition 2b,Condition 2c,Condition 3a,Condition 3b,Condition 3c 751,"Van Dijk SJ, et al., Nephron Exp Nephrol 2005 Jun 20;101(2):e59-e66.",kidney glomerulus integrity trait,,RS:0000021,ACI/Eur,male,180 days to 173 days,8,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,,,6,%,2.0,5.6569,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,controlled NG-nitroarginine methyl ester content in acidified drinking water (8-13 mg/kg/d) (for 126 days),67953,controlled NG-nitroarginine methyl ester content in acidified drinking water (8-13 mg/kg/d) (for 126 days),,,,,,,, 751,"Van Dijk SJ, et al., Nephron Exp Nephrol 2005 Jun 20;101(2):e59-e66.",kidney glomerulus integrity trait,,RS:0000016,ACI.FHH-(D17Rat117-D17Arb5)(D17Rat180-D17Rat51)/Eur,male,180 days to 173 days,9,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,,,5,%,6.0,18.0,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,controlled NG-nitroarginine methyl ester content in acidified drinking water (8-13 mg/kg/d) (for 126 days),67954,controlled NG-nitroarginine methyl ester content in acidified drinking water (8-13 mg/kg/d) (for 126 days),,,,,,,, 751,"Van Dijk SJ, et al., Nephron Exp Nephrol 2005 Jun 20;101(2):e59-e66.",kidney glomerulus integrity trait,,RS:0000020,ACI.FHH-(D1Rat324-D1Rat156)/Eur,male,180 days to 173 days,7,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,,,16,%,5.0,13.2288,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,controlled NG-nitroarginine methyl ester content in acidified drinking water (8-13 mg/kg/d) (for 126 days),67955,controlled NG-nitroarginine methyl ester content in acidified drinking water (8-13 mg/kg/d) (for 126 days),,,,,,,, 751,"Van Dijk SJ, et al., Nephron Exp Nephrol 2005 Jun 20;101(2):e59-e66.",kidney glomerulus integrity trait,,RS:0000021,ACI/Eur,male,180 days to 173 days,8,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,,,5,%,1.0,2.8284,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,unilateral nephrectomy then controlled hydrogen ion content drinking water (2.4-2.8 pH) ,67956,unilateral nephrectomy,,,controlled hydrogen ion content drinking water (2.4-2.8 pH) ,,,,, 751,"Van Dijk SJ, et al., Nephron Exp Nephrol 2005 Jun 20;101(2):e59-e66.",kidney glomerulus integrity trait,,RS:0000016,ACI.FHH-(D17Rat117-D17Arb5)(D17Rat180-D17Rat51)/Eur,male,180 days to 173 days,10,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,,,2,%,1.0,3.1623,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,unilateral nephrectomy then controlled hydrogen ion content drinking water (2.4-2.8 pH) ,67957,unilateral nephrectomy,,,controlled hydrogen ion content drinking water (2.4-2.8 pH) ,,,,, 751,"Van Dijk SJ, et al., Nephron Exp Nephrol 2005 Jun 20;101(2):e59-e66.",kidney glomerulus integrity trait,,RS:0000020,ACI.FHH-(D1Rat324-D1Rat156)/Eur,male,180 days to 173 days,8,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,,,9,%,3.0,8.4853,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,unilateral nephrectomy then controlled hydrogen ion content drinking water (2.4-2.8 pH) ,67958,unilateral nephrectomy,,,controlled hydrogen ion content drinking water (2.4-2.8 pH) ,,,,, 751,"Van Dijk SJ, et al., Nephron Exp Nephrol 2005 Jun 20;101(2):e59-e66.",kidney glomerulus integrity trait,,RS:0000021,ACI/Eur,male,180 days to 173 days,11,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,,,13,%,2.0,6.6332,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,unilateral nephrectomy then controlled NG-nitroarginine methyl ester content in acidified drinking water (11-15 mg/kg/d) (for 126 days),67959,unilateral nephrectomy,,,controlled NG-nitroarginine methyl ester content in acidified drinking water (11-15 mg/kg/d) (for 126 days),,,,, 751,"Van Dijk SJ, et al., Nephron Exp Nephrol 2005 Jun 20;101(2):e59-e66.",kidney glomerulus integrity trait,,RS:0000016,ACI.FHH-(D17Rat117-D17Arb5)(D17Rat180-D17Rat51)/Eur,male,180 days to 173 days,9,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,,,8,%,2.0,6.0,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,unilateral nephrectomy then controlled NG-nitroarginine methyl ester content in acidified drinking water (11-15 mg/kg/d) (for 126 days),67960,unilateral nephrectomy,,,controlled NG-nitroarginine methyl ester content in acidified drinking water (11-15 mg/kg/d) (for 126 days),,,,, 751,"Van Dijk SJ, et al., Nephron Exp Nephrol 2005 Jun 20;101(2):e59-e66.",kidney glomerulus integrity trait,,RS:0000021,ACI/Eur,male,98 days,15,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,,,6,%,1.0,3.873,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,controlled hydrogen ion content drinking water (2.4-2.8 pH) ,68044,controlled hydrogen ion content drinking water (2.4-2.8 pH) ,,,,,,,, 751,"Van Dijk SJ, et al., Nephron Exp Nephrol 2005 Jun 20;101(2):e59-e66.",kidney glomerulus integrity trait,,RS:0000016,ACI.FHH-(D17Rat117-D17Arb5)(D17Rat180-D17Rat51)/Eur,male,98 days,15,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,,,5,%,1.0,3.873,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,controlled hydrogen ion content drinking water (2.4-2.8 pH) ,68045,controlled hydrogen ion content drinking water (2.4-2.8 pH) ,,,,,,,, 751,"Van Dijk SJ, et al., Nephron Exp Nephrol 2005 Jun 20;101(2):e59-e66.",kidney glomerulus integrity trait,,RS:0000018,FHH/Eur,male,98 days,15,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,,,13,%,1.0,3.873,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,controlled hydrogen ion content drinking water (2.4-2.8 pH) ,68046,controlled hydrogen ion content drinking water (2.4-2.8 pH) ,,,,,,,, 751,"Van Dijk SJ, et al., Nephron Exp Nephrol 2005 Jun 20;101(2):e59-e66.",kidney glomerulus integrity trait,,RS:0000020,ACI.FHH-(D1Rat324-D1Rat156)/Eur,male,98 days,18,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,,,10,%,1.0,4.2426,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,controlled hydrogen ion content drinking water (2.4-2.8 pH) ,68047,controlled hydrogen ion content drinking water (2.4-2.8 pH) ,,,,,,,, 751,"Van Dijk SJ, et al., Nephron Exp Nephrol 2005 Jun 20;101(2):e59-e66.",kidney glomerulus integrity trait,,RS:0000020,ACI.FHH-(D1Rat324-D1Rat156)/Eur,male,180 days to 173 days,8,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,% glomerulosclerosis,,41,%,9.0,25.4558,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,unilateral nephrectomy then controlled NG-nitroarginine methyl ester content in acidified drinking water (11-15 mg/kg/d) (for 126 days),67961,unilateral nephrectomy,,,controlled NG-nitroarginine methyl ester content in acidified drinking water (11-15 mg/kg/d) (for 126 days),,,,, 2601,"Velasquez MT, et al., Hypertension. 1997 Nov;30(5):1232-7.",kidney glomerulus integrity trait,,RS:0000750,SHR/N-cp,male,196 days to 168 days,8,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,,,16,%,3.0,8.4853,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,standard diet (between 28 and 42 days) then controlled carbohydrate content diet (54 %) (between 140 and 154 days),101526,standard diet (between 28 and 42 days),,,controlled carbohydrate content diet (54 %) (between 140 and 154 days),,,,, 2601,"Velasquez MT, et al., Hypertension. 1997 Nov;30(5):1232-7.",kidney glomerulus integrity trait,,RS:0000750,SHR/N-cp,male,196 days to 168 days,8,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,,,9,%,4.0,11.3137,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,standard diet (between 28 and 42 days) then controlled carbohydrate content diet (54 %) (between 140 and 154 days) then perindopril (0.25-0.5 mg/kg/d) (between 84 and 98 days),101527,standard diet (between 28 and 42 days),,,controlled carbohydrate content diet (54 %) (between 140 and 154 days),,,perindopril (0.25-0.5 mg/kg/d) (between 84 and 98 days),, 2601,"Velasquez MT, et al., Hypertension. 1997 Nov;30(5):1232-7.",kidney glomerulus integrity trait,,RS:0000750,SHR/N-cp,male,168 days to 140 days,8,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,,,4,%,1.0,2.8284,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,standard diet (between 28 and 42 days) then controlled carbohydrate content diet (54 %) (between 140 and 154 days) then controlled hydralazine content drinking water (30 mg/l) (between 84 and 98 days) and hydralazine (50 mg/l) (between 84 and 98 days) and reserpine (4 mg/l) (between 84 and 98 days),101528,standard diet (between 28 and 42 days),,,controlled carbohydrate content diet (54 %) (between 140 and 154 days),,,controlled hydralazine content drinking water (30 mg/l) (between 84 and 98 days),hydralazine (50 mg/l) (between 84 and 98 days),reserpine (4 mg/l) (between 84 and 98 days) 2741,"Dang R, etal., PLoS One. 2011;6(9):e24086. Epub 2011 Sep 7.",colorectal integrity trait,,RS:0003208,AR-Ednrbsl/Hkv,male,14 days,17,,CMO:0001839,percentage of study population developing colonic aganglionosis during a period of time,,,,100,%,,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,specific pathogen-free condition,102828,specific pathogen-free condition,,,,,,,, 2741,"Dang R, etal., PLoS One. 2011;6(9):e24086. Epub 2011 Sep 7.",colorectal integrity trait,,RS:0003208,AR-Ednrbsl/Hkv,female,14 days,15,,CMO:0001839,percentage of study population developing colonic aganglionosis during a period of time,,,,100,%,,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,specific pathogen-free condition,102829,specific pathogen-free condition,,,,,,,, 2741,"Dang R, etal., PLoS One. 2011;6(9):e24086. Epub 2011 Sep 7.",colorectal integrity trait,,RS:0003209,LEH/Hkv,male,14 days,12,,CMO:0001839,percentage of study population developing colonic aganglionosis during a period of time,,,,100,%,,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,specific pathogen-free condition,102830,specific pathogen-free condition,,,,,,,, 2741,"Dang R, etal., PLoS One. 2011;6(9):e24086. Epub 2011 Sep 7.",colorectal integrity trait,,RS:0003209,LEH/Hkv,female,14 days,15,,CMO:0001839,percentage of study population developing colonic aganglionosis during a period of time,,,,100,%,,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,specific pathogen-free condition,102831,specific pathogen-free condition,,,,,,,, 2741,"Dang R, etal., PLoS One. 2011;6(9):e24086. Epub 2011 Sep 7.",colorectal integrity trait,,RS:0003210,F344.AR-EdnrbslHkv,male,14 days,32,,CMO:0001839,percentage of study population developing colonic aganglionosis during a period of time,,,,53,%,,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,specific pathogen-free condition,102832,specific pathogen-free condition,,,,,,,, 2741,"Dang R, etal., PLoS One. 2011;6(9):e24086. Epub 2011 Sep 7.",colorectal integrity trait,,RS:0003210,F344.AR-EdnrbslHkv,female,14 days,21,,CMO:0001839,percentage of study population developing colonic aganglionosis during a period of time,,,,38,%,,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,specific pathogen-free condition,102833,specific pathogen-free condition,,,,,,,, 2339,"Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502.",hippocampus neuron quantity,,RS:0003328,SS/NEisSlc,not specified,547 days,10,,CMO:0000328,neuron count,,,,1466,cells/mm2,42.0,132.8157,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,controlled cilazapril content drinking water (0.16 mg/kg/d) (for 547.5 days),107466,controlled cilazapril content drinking water (0.16 mg/kg/d) (for 547.5 days),,,,,,,, 2339,"Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502.",hippocampus neuron quantity,,RS:0003328,SS/NEisSlc,not specified,547 days,10,,CMO:0000328,neuron count,,,,1491,cells/mm2,57.0,180.2498,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,controlled cilazapril content drinking water (0.94 mg/kg/d) (for 547.5 days),107467,controlled cilazapril content drinking water (0.94 mg/kg/d) (for 547.5 days),,,,,,,, 2339,"Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502.",hippocampus neuron quantity,,RS:0003328,SS/NEisSlc,not specified,547 days,10,,CMO:0000328,neuron count,,,,1258,cells/mm2,32.0,101.1929,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,vehicle control condition (for 547.5 days),107465,vehicle control condition (for 547.5 days),,,,,,,, 2519,"Otsuka F, et al., Am J Physiol. 1998 Jun;274(6 Pt 2):R1797-806.",kidney glomerulus morphology trait,,RS:0003328,SS/NEisSlc,male,91 days,12,,CMO:0002959,number of nucleated cells per kidney glomerulus,,,,77.8,,1.44,4.9883,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,controlled sodium content diet (8 %) (for 42 days) then 0.9% sodium chloride solution (0.3 ml) (for 42 days),100726,controlled sodium content diet (8 %) (for 42 days),,,0.9% sodium chloride solution (0.3 ml) (for 42 days),,,,, 2519,"Otsuka F, et al., Am J Physiol. 1998 Jun;274(6 Pt 2):R1797-806.",kidney glomerulus morphology trait,,RS:0003328,SS/NEisSlc,male,91 days,6,,CMO:0002959,number of nucleated cells per kidney glomerulus,,,,41.2,,1.37,3.3558,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,controlled sodium content diet (0.3 %) (for 91 days),100727,controlled sodium content diet (0.3 %) (for 91 days),,,,,,,, 2519,"Otsuka F, et al., Am J Physiol. 1998 Jun;274(6 Pt 2):R1797-806.",kidney glomerulus morphology trait,,RS:0003329,SR/NEisSlc,male,91 days,6,,CMO:0002959,number of nucleated cells per kidney glomerulus,,,,33,,0.75,1.8371,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,controlled sodium content diet (0.3 %) (for 91 days),100728,controlled sodium content diet (0.3 %) (for 91 days),,,,,,,, 2519,"Otsuka F, et al., Am J Physiol. 1998 Jun;274(6 Pt 2):R1797-806.",kidney glomerulus morphology trait,,RS:0003328,SS/NEisSlc,male,91 days,6,,CMO:0002959,number of nucleated cells per kidney glomerulus,,,,51.7,,1.2,2.9394,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,controlled sodium content diet (8 %) (for 42 days) then cilazapril (10 mg/kg/d) (for 42 days),100729,controlled sodium content diet (8 %) (for 42 days),,,cilazapril (10 mg/kg/d) (for 42 days),,,,, 2519,"Otsuka F, et al., Am J Physiol. 1998 Jun;274(6 Pt 2):R1797-806.",kidney glomerulus morphology trait,,RS:0003328,SS/NEisSlc,male,91 days,6,,CMO:0002959,number of nucleated cells per kidney glomerulus,,,,50.4,,1.25,3.0619,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,controlled sodium content diet (8 %) (for 42 days) then candesartan (1 mg/kg/d) (for 42 days),100730,controlled sodium content diet (8 %) (for 42 days),,,candesartan (1 mg/kg/d) (for 42 days),,,,, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney glomerulus size trait,,RS:0000742,WKY,male,0 days,17,,CMO:0003489,kidney glomerular tuft surface area,,,,13.2,x 10E3 um2,3.3,13.6062,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then vehicle control condition,107511,unilateral nephrectomy (for 150 days),,,streptozotocin (35 mg/kg) ,,,vehicle control condition,, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney glomerulus size trait,,RS:0000742,WKY,male,0 days,17,,CMO:0003489,kidney glomerular tuft surface area,,kidney glomerulus surface area (CMO:0003488),,11.8,x 10E3 um2,2.9,11.957,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 136 days),107512,unilateral nephrectomy (for 150 days),,,streptozotocin (35 mg/kg) ,,,bosentan (100 mg/kg/d) (for 136 days),, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney glomerulus size trait,,RS:0000742,WKY,male,0 days,16,,CMO:0003489,kidney glomerular tuft surface area,,,,11.7,x 10E3 um2,2.9,11.6,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 136 days) and bosentan (100 mg/kg/d) (for 136 days),107514,unilateral nephrectomy (for 150 days),,,streptozotocin (35 mg/kg) ,,,enalapril (10 mg/kg/d) (for 136 days),bosentan (100 mg/kg/d) (for 136 days), 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney glomerulus size trait,,RS:0000742,WKY,male,0 days,16,,CMO:0003488,kidney glomerular surface area,,kidney glomerulus surface area (CMO:0003488),,16.4,x 10E3 um2,4.1,16.4,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 136 days) and bosentan (100 mg/kg/d) (for 136 days),107464,unilateral nephrectomy (for 150 days),,,streptozotocin (35 mg/kg) ,,,enalapril (10 mg/kg/d) (for 136 days),bosentan (100 mg/kg/d) (for 136 days), 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney glomerulus size trait,,RS:0000742,WKY,male,0 days,17,,CMO:0003488,kidney glomerular surface area,,kidney glomerulus surface area (CMO:0003488),,19.3,x 10E3 um2,4.8,19.7909,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then vehicle control condition,107461,unilateral nephrectomy (for 150 days),,,streptozotocin (35 mg/kg) ,,,vehicle control condition,, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney glomerulus size trait,,RS:0000742,WKY,male,0 days,11,,CMO:0003489,kidney glomerular tuft surface area,,,,8.7,x 10E3 um2,2.6,8.6232,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then vehicle control condition,107510,unilateral nephrectomy (for 150 days),,,vehicle control condition,,,,, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney glomerulus size trait,,RS:0000742,WKY,male,0 days,16,,CMO:0003489,kidney glomerular tuft surface area,,kidney glomerulus surface area (CMO:0003488),,11.1,x 10E3 um2,2.8,11.2,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 136 days),107513,unilateral nephrectomy (for 150 days),,,streptozotocin (35 mg/kg) ,,,enalapril (10 mg/kg/d) (for 136 days),, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney glomerulus size trait,,RS:0000742,WKY,male,0 days,11,,CMO:0003488,kidney glomerular surface area,,kidney glomerulus surface area (CMO:0003488),,12.6,x 10E3 um2,3.8,12.6032,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then vehicle control condition,107460,unilateral nephrectomy (for 150 days),,,vehicle control condition,,,,, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney glomerulus size trait,,RS:0000742,WKY,male,0 days,17,,CMO:0003488,kidney glomerular surface area,,kidney glomerulus surface area (CMO:0003488),,17,x 10E3 um2,4.1,16.9047,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 136 days),107462,unilateral nephrectomy (for 150 days),,,streptozotocin (35 mg/kg) ,,,bosentan (100 mg/kg/d) (for 136 days),, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney glomerulus size trait,,RS:0000742,WKY,male,0 days,16,,CMO:0003488,kidney glomerular surface area,,kidney glomerulus surface area (CMO:0003488),,15.8,x 10E3 um2,4.0,16.0,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 136 days),107463,unilateral nephrectomy (for 150 days),,,streptozotocin (35 mg/kg) ,,,enalapril (10 mg/kg/d) (for 136 days),, 2158,"Jiang JT, et al., Toxicology. 2015 Dec 2;338:77-85. doi: 10.1016/j.tox.2015.10.006. Epub 2015 Oct 26.",anorectal integrity trait,,RS:0000681,SD,male,1 days,43,,CMO:0002754,percentage of study population developing anorectal malformation during a period of time,,anorectal malformation incidence,,39.5,%,,,MMO:0000561,ex vivo light microscopy with histochemistry,,1.0,,,,,in utero condition (for 7 days) and dibutyl phthalate (850 mg/kg/d) (for 7 days),98733,in utero condition (for 7 days),dibutyl phthalate (850 mg/kg/d) (for 7 days),,,,,,, 2158,"Jiang JT, et al., Toxicology. 2015 Dec 2;338:77-85. doi: 10.1016/j.tox.2015.10.006. Epub 2015 Oct 26.",anorectal integrity trait,,RS:0000681,SD,male,1 days,N/A,,CMO:0002754,percentage of study population developing anorectal malformation during a period of time,,anorectal malformation incidence,,0,%,,,MMO:0000561,ex vivo light microscopy with histochemistry,,1.0,,,,,in utero condition (for 7 days) and corn oil (for 7 days),98734,in utero condition (for 7 days),corn oil (for 7 days),,,,,,, 2602,"Greene EL, et al., J Clin Invest. 1996 Aug 15;98(4):1063-8.",kidney glomerulus integrity trait,,RS:0000681,SD,male,0 days,6,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,,,1.9,%,0.4899,1.2,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,sham unx,28,days,sham surgical control condition (for 28 days),101603,sham surgical control condition (for 28 days),,,,,,,, 2602,"Greene EL, et al., J Clin Invest. 1996 Aug 15;98(4):1063-8.",kidney glomerulus integrity trait,,RS:0000681,SD,male,0 days,7,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,,,37.2,%,10.0161,26.5,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days),101604,unilateral nephrectomy (for 28 days),,,,,,,, 2602,"Greene EL, et al., J Clin Invest. 1996 Aug 15;98(4):1063-8.",kidney glomerulus integrity trait,,RS:0000681,SD,male,0 days,7,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,,,4.7,%,1.9654,5.2,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then enalapril (50 mg/l) (for 28 days) and losartan (180 mg/l) (for 28 days),101605,unilateral nephrectomy (for 28 days),,,enalapril (50 mg/l) (for 28 days),losartan (180 mg/l) (for 28 days),,,, 2602,"Greene EL, et al., J Clin Invest. 1996 Aug 15;98(4):1063-8.",kidney glomerulus integrity trait,,RS:0000681,SD,male,0 days,6,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,,,25.3,%,4.5316,11.1,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then enalapril (50 mg/l) (for 28 days) and losartan (180 mg/l) (for 28 days) and aldosterone (35 mg/kg/d) (for 28 days),101606,unilateral nephrectomy (for 28 days),,,enalapril (50 mg/l) (for 28 days),losartan (180 mg/l) (for 28 days),aldosterone (35 mg/kg/d) (for 28 days),,, 2602,"Greene EL, et al., J Clin Invest. 1996 Aug 15;98(4):1063-8.",kidney glomerulus integrity trait,,RS:0000681,SD,male,0 days,8,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,,,31,%,5.6569,16.0,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days),101629,unilateral nephrectomy (for 28 days),,,,,,,, 2602,"Greene EL, et al., J Clin Invest. 1996 Aug 15;98(4):1063-8.",kidney glomerulus integrity trait,,RS:0000681,SD,male,0 days,8,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,,,26,%,3.8891,11.0,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then spironolactone (5.56 mg/kg/d) (for 28 days),101630,unilateral nephrectomy (for 28 days),,,spironolactone (5.56 mg/kg/d) (for 28 days),,,,, 3099,"Pirici D, etal., Brain Pathol. 2017 Mar;27(2):169-180. doi: 10.1111/bpa.12384. Epub 2016 May 30.",cerebral cortex integrity trait,,RS:0002538,SHRSP/A3NCrl,male,308 days to 84 days,80,,CMO:0003501,percentage of study population developing cerebral small vessel thrombosis and adjacent tissue infarction during a period of time,,,,9,%,,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,107918,control condition,,,,,,,, 3099,"Pirici D, etal., Brain Pathol. 2017 Mar;27(2):169-180. doi: 10.1111/bpa.12384. Epub 2016 May 30.",cerebral cortex integrity trait,,RS:0002538,SHRSP/A3NCrl,male,308 days to 84 days,80,,CMO:0003499,percentage of study population developing cerebral beta-amyloid deposits during a period of time,,,,23,%,,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,107916,control condition,,,,,,,, 3099,"Pirici D, etal., Brain Pathol. 2017 Mar;27(2):169-180. doi: 10.1111/bpa.12384. Epub 2016 May 30.",kidney integrity trait,,RS:0002538,SHRSP/A3NCrl,male,308 days to 98 days,80,,CMO:0003649,percentage of study population developing kidney tubulointerstitial damage during a period of time,,percentage of study population developing kidney tubulointerstitial damage during a period of time (CMO:0003649),,85,%,,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,107919,control condition,,,,,,,, 3099,"Pirici D, etal., Brain Pathol. 2017 Mar;27(2):169-180. doi: 10.1111/bpa.12384. Epub 2016 May 30.",cerebral cortex integrity trait,,RS:0002538,SHRSP/A3NCrl,male,308 days to 84 days,62,,CMO:0003503,percentage of study population developing cerebral small perivascular bleeds and no beta-amyloid deposits during a period of time,,,,26,%,,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,107922,control condition,,,,,,,, 3099,"Pirici D, etal., Brain Pathol. 2017 Mar;27(2):169-180. doi: 10.1111/bpa.12384. Epub 2016 May 30.",cerebral cortex integrity trait,,RS:0002538,SHRSP/A3NCrl,male,308 days to 84 days,80,,CMO:0003500,percentage of study population developing cerebral small perivascular bleeds during a period of time,,,,33,%,,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,107917,control condition,,,,,,,, 3099,"Pirici D, etal., Brain Pathol. 2017 Mar;27(2):169-180. doi: 10.1111/bpa.12384. Epub 2016 May 30.",kidney integrity trait,,RS:0002538,SHRSP/A3NCrl,male,308 days to 168 days,80,,CMO:0003504,percentage of study population developing renal vascular pathology during a period of time,,,,45,%,,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,107920,control condition,,,,,,,, 3099,"Pirici D, etal., Brain Pathol. 2017 Mar;27(2):169-180. doi: 10.1111/bpa.12384. Epub 2016 May 30.",cerebral cortex integrity trait,,RS:0002538,SHRSP/A3NCrl,male,308 days to 84 days,18,,CMO:0003502,percentage of study population developing cerebral small perivascular bleeds and beta-amyloid deposits during a period of time,,,,56,%,,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,107921,control condition,,,,,,,, 3090,"Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21.",kidney glomerulus integrity trait,,RS:0000775,SHRSP/A3N,male,182 days to 126 days,N/A,,CMO:0003447,kidney glomerular lesion count,,,,1.4,/section,1.0,,MMO:0000561,ex vivo light microscopy with histochemistry,renal glomerulus,0.0,,,,,controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and eprosartan (60 mg/kg/d) (between 42 and 77 days),107540,controlled sodium chloride content drinking water (1 %) (between 42 and 77 days),controlled fat content diet (24.5 %) (between 42 and 77 days),eprosartan (60 mg/kg/d) (between 42 and 77 days),,,,,, 3090,"Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21.",kidney integrity trait,,RS:0000714,WKY/N,male,182 days to 126 days,N/A,,CMO:0003443,kidney tubule regeneration foci count,,,,0.25,/section,0.25,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,107545,control condition,,,,,,,, 3090,"Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21.",kidney integrity trait,,RS:0000775,SHRSP/A3N,male,182 days to 126 days,N/A,,CMO:0003443,kidney tubule regeneration foci count,,,,1.3,/section,0.3,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,107546,control condition,,,,,,,, 3090,"Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21.",kidney integrity trait,,RS:0000775,SHRSP/A3N,male,182 days to 126 days,N/A,,CMO:0003443,kidney tubule regeneration foci count,,,,27.3,/section,2.9,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and vehicle control condition (between 42 and 77 days),107547,controlled sodium chloride content drinking water (1 %) (between 42 and 77 days),controlled fat content diet (24.5 %) (between 42 and 77 days),vehicle control condition (between 42 and 77 days),,,,,, 3090,"Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21.",kidney integrity trait,,RS:0000775,SHRSP/A3N,male,182 days to 126 days,N/A,,CMO:0003443,kidney tubule regeneration foci count,,,,0,/section,0.0,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and eprosartan (60 mg/kg/d) (between 42 and 77 days),107548,controlled sodium chloride content drinking water (1 %) (between 42 and 77 days),controlled fat content diet (24.5 %) (between 42 and 77 days),eprosartan (60 mg/kg/d) (between 42 and 77 days),,,,,, 3090,"Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21.",kidney integrity trait,,RS:0000714,WKY/N,male,182 days to 126 days,N/A,,CMO:0003445,interstitial nephritis foci count,,,,0.5,/section,0.3,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,107549,control condition,,,,,,,, 3090,"Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21.",kidney integrity trait,,RS:0000775,SHRSP/A3N,male,182 days to 126 days,N/A,,CMO:0003445,interstitial nephritis foci count,,,,4.9,/section,1.0,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,107550,control condition,,,,,,,, 3090,"Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21.",kidney integrity trait,,RS:0000775,SHRSP/A3N,male,182 days to 126 days,N/A,,CMO:0003445,interstitial nephritis foci count,,,,8.5,/section,1.2,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and vehicle control condition (between 42 and 77 days),107551,controlled sodium chloride content drinking water (1 %) (between 42 and 77 days),controlled fat content diet (24.5 %) (between 42 and 77 days),vehicle control condition (between 42 and 77 days),,,,,, 3090,"Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21.",kidney integrity trait,,RS:0000775,SHRSP/A3N,male,182 days to 126 days,N/A,,CMO:0003445,interstitial nephritis foci count,,,,1,/section,0.4,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and eprosartan (60 mg/kg/d) (between 42 and 77 days),107552,controlled sodium chloride content drinking water (1 %) (between 42 and 77 days),controlled fat content diet (24.5 %) (between 42 and 77 days),eprosartan (60 mg/kg/d) (between 42 and 77 days),,,,,, 3090,"Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21.",kidney integrity trait,,RS:0000775,SHRSP/A3N,male,182 days to 126 days,N/A,,CMO:0003444,kidney total tubule cast count,,,,4,/section,3.0,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and eprosartan (60 mg/kg/d) (between 42 and 77 days),107556,controlled sodium chloride content drinking water (1 %) (between 42 and 77 days),controlled fat content diet (24.5 %) (between 42 and 77 days),eprosartan (60 mg/kg/d) (between 42 and 77 days),,,,,, 3090,"Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21.",kidney integrity trait,,RS:0000714,WKY/N,male,182 days to 126 days,N/A,,CMO:0003444,kidney total tubule cast count,,,,1,/section,1.0,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,107553,control condition,,,,,,,, 3090,"Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21.",kidney integrity trait,,RS:0000775,SHRSP/A3N,male,182 days to 126 days,N/A,,CMO:0003444,kidney total tubule cast count,,,,21,/section,5.0,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,107554,control condition,,,,,,,, 3090,"Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21.",kidney integrity trait,,RS:0000775,SHRSP/A3N,male,182 days to 126 days,N/A,,CMO:0003444,kidney total tubule cast count,,,,349,/section,45.0,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and vehicle control condition (between 42 and 77 days),107555,controlled sodium chloride content drinking water (1 %) (between 42 and 77 days),controlled fat content diet (24.5 %) (between 42 and 77 days),vehicle control condition (between 42 and 77 days),,,,,, 3090,"Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21.",kidney integrity trait,,RS:0000714,WKY/N,male,182 days to 126 days,N/A,,CMO:0003446,renal fibrosis foci count,,,,5.9,/section,0.7,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,107557,control condition,,,,,,,, 3090,"Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21.",kidney integrity trait,,RS:0000775,SHRSP/A3N,male,182 days to 126 days,N/A,,CMO:0003446,renal fibrosis foci count,,,,7.4,/section,0.4,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,107558,control condition,,,,,,,, 3090,"Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21.",kidney integrity trait,,RS:0000775,SHRSP/A3N,male,182 days to 126 days,N/A,,CMO:0003446,renal fibrosis foci count,,,,16.4,/section,1.4,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and vehicle control condition (between 42 and 77 days),107559,controlled sodium chloride content drinking water (1 %) (between 42 and 77 days),controlled fat content diet (24.5 %) (between 42 and 77 days),vehicle control condition (between 42 and 77 days),,,,,, 3090,"Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21.",kidney integrity trait,,RS:0000775,SHRSP/A3N,male,182 days to 126 days,N/A,,CMO:0003446,renal fibrosis foci count,,,,7.1,/section,0.3,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and eprosartan (60 mg/kg/d) (between 42 and 77 days),107560,controlled sodium chloride content drinking water (1 %) (between 42 and 77 days),controlled fat content diet (24.5 %) (between 42 and 77 days),eprosartan (60 mg/kg/d) (between 42 and 77 days),,,,,, 3090,"Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21.",kidney glomerulus integrity trait,,RS:0000714,WKY/N,male,182 days to 126 days,N/A,,CMO:0003447,kidney glomerular lesion count,,,,0.8,/section,0.5,,MMO:0000561,ex vivo light microscopy with histochemistry,renal glomerulus,0.0,,,,,control condition,107537,control condition,,,,,,,, 3090,"Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21.",kidney glomerulus integrity trait,,RS:0000775,SHRSP/A3N,male,182 days to 126 days,N/A,,CMO:0003447,kidney glomerular lesion count,,,,8.8,/section,2.7,,MMO:0000561,ex vivo light microscopy with histochemistry,renal glomerulus,0.0,,,,,control condition,107538,control condition,,,,,,,, 3090,"Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21.",kidney glomerulus integrity trait,,RS:0000775,SHRSP/A3N,male,182 days to 126 days,N/A,,CMO:0003447,kidney glomerular lesion count,,,,76.5,/section,7.0,,MMO:0000561,ex vivo light microscopy with histochemistry,renal glomerulus,0.0,,,,,controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and vehicle control condition (between 42 and 77 days),107539,controlled sodium chloride content drinking water (1 %) (between 42 and 77 days),controlled fat content diet (24.5 %) (between 42 and 77 days),vehicle control condition (between 42 and 77 days),,,,,, 3110,"Kondo H, etal., Muscle Nerve. 2015 Mar;51(3):391-9. doi: 10.1002/mus.24316. Epub 2015 Jan 6.",skeletal muscle capillary amount,,RS:0001299,GK,male,63 days,6,,CMO:0003593,capillary number to soleus muscle fiber number ratio,,,,1.98,,0.16,0.3919,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,running on treadmill (15 m/min) (for 1 hours),108122,running on treadmill (15 m/min) (for 1 hours),,,,,,,, 3110,"Kondo H, etal., Muscle Nerve. 2015 Mar;51(3):391-9. doi: 10.1002/mus.24316. Epub 2015 Jan 6.",skeletal muscle capillary amount,,RS:0001299,GK,male,63 days,6,,CMO:0003593,capillary number to soleus muscle fiber number ratio,,,,2,,0.04,0.098,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,108121,control condition,,,,,,,, 3110,"Kondo H, etal., Muscle Nerve. 2015 Mar;51(3):391-9. doi: 10.1002/mus.24316. Epub 2015 Jan 6.",skeletal muscle capillary amount,,RS:0000963,W/Kyo,male,63 days,6,,CMO:0003593,capillary number to soleus muscle fiber number ratio,,,,1.85,,0.11,0.2694,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,108119,control condition,,,,,,,, 3110,"Kondo H, etal., Muscle Nerve. 2015 Mar;51(3):391-9. doi: 10.1002/mus.24316. Epub 2015 Jan 6.",skeletal muscle capillary amount,,RS:0000963,W/Kyo,male,63 days,6,,CMO:0003593,capillary number to soleus muscle fiber number ratio,,,,1.95,,0.12,0.2939,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,running on treadmill (15 m/min) (for 1 hours),108120,running on treadmill (15 m/min) (for 1 hours),,,,,,,, 3016,"Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31.",retinal outer nuclear layer morphology trait,,RS:0000064,Crl:CD(SD),male,144 days to 137 days,5,,CMO:0003085,retinal outer nuclear layer photoreceptor nucleus count,,nuclei per cell,,8.4,,0.4919,1.1,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,AMG-8718 (600 mg/kg) (for 25 days),105465,AMG-8718 (600 mg/kg) (for 25 days),,,,,,,, 3016,"Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31.",retinal outer nuclear layer morphology trait,,RS:0000064,Crl:CD(SD),male,144 days to 137 days,5,,CMO:0003085,retinal outer nuclear layer photoreceptor nucleus count,,nuclei per cell,,10.5,,0.4025,0.9,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,vehicle control condition (for 25 days),105462,vehicle control condition (for 25 days),,,,,,,, 3016,"Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31.",retinal outer nuclear layer morphology trait,,RS:0000064,Crl:CD(SD),male,144 days to 137 days,5,,CMO:0003085,retinal outer nuclear layer photoreceptor nucleus count,,nuclei per cell,,10.7,,0.4025,0.9,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,AMG-8718 (10 mg/kg) (for 25 days),105463,AMG-8718 (10 mg/kg) (for 25 days),,,,,,,, 3016,"Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31.",retinal outer nuclear layer morphology trait,,RS:0000064,Crl:CD(SD),male,144 days to 137 days,5,,CMO:0003085,retinal outer nuclear layer photoreceptor nucleus count,,nuclei per cell,,10.1,,0.4025,0.9,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,AMG-8718 (100 mg/kg) (for 25 days),105464,AMG-8718 (100 mg/kg) (for 25 days),,,,,,,, 3016,"Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31.",retinal outer nuclear layer morphology trait,,RS:0000064,Crl:CD(SD),male,88 days to 81 days,5,,CMO:0003085,retinal outer nuclear layer photoreceptor nucleus count,,nuclei per cell,,11.3,,0.3712,0.83,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,vehicle control condition (0 mg/kg) (for 25 days),105450,vehicle control condition (0 mg/kg) (for 25 days),,,,,,,, 3016,"Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31.",retinal outer nuclear layer morphology trait,,RS:0000064,Crl:CD(SD),male,88 days to 81 days,5,,CMO:0003085,retinal outer nuclear layer photoreceptor nucleus count,,nuclei per cell,,11.3,,0.322,0.72,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,AMG-8718 (10 mg/kg) (for 25 days),105451,AMG-8718 (10 mg/kg) (for 25 days),,,,,,,, 3016,"Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31.",retinal outer nuclear layer morphology trait,,RS:0000064,Crl:CD(SD),male,88 days to 81 days,5,,CMO:0003085,retinal outer nuclear layer photoreceptor nucleus count,,nuclei per cell,,11.7,,0.313,0.7,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,AMG-8718 (100 mg/kg) (for 25 days),105452,AMG-8718 (100 mg/kg) (for 25 days),,,,,,,, 3016,"Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31.",retinal outer nuclear layer morphology trait,,RS:0000064,Crl:CD(SD),male,88 days to 81 days,5,,CMO:0003085,retinal outer nuclear layer photoreceptor nucleus count,,nuclei per cell,,10.5,,0.4249,0.95,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,AMG-8718 (600 mg/kg) (for 25 days),105453,AMG-8718 (600 mg/kg) (for 25 days),,,,,,,, 3082,"Kang S, et al., Transl Vis Sci Technol. 2019 Aug 7;8(4):19. doi: 10.1167/tvst.8.4.19. eCollection 2019 Jul.",retinal photoreceptor quantity,,RS:0000655,RCS-p+/LavRrrc,not specified,180 days,8,,CMO:0003442,retinal outer nuclear layer photoreceptor nucleus count to layer length ratio,,,,3,/ 100 um,2.5,7.0711,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,experimental eye,SRT,161,days,subthreshold laser therapy (200 um) (for 0 hours),109067,subthreshold laser therapy (200 um) (for 0 hours),,,,,,,, 3082,"Kang S, et al., Transl Vis Sci Technol. 2019 Aug 7;8(4):19. doi: 10.1167/tvst.8.4.19. eCollection 2019 Jul.",retinal photoreceptor quantity,,RS:0000655,RCS-p+/LavRrrc,not specified,180 days,8,,CMO:0003442,retinal outer nuclear layer photoreceptor nucleus count to layer length ratio,,,,2.3,/ 100 um,1.3,3.677,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,contralateral control eye,,,,control condition,109068,control condition,,,,,,,, 3082,"Kang S, et al., Transl Vis Sci Technol. 2019 Aug 7;8(4):19. doi: 10.1167/tvst.8.4.19. eCollection 2019 Jul.",retinal photoreceptor quantity,,RS:0000655,RCS-p+/LavRrrc,not specified,180 days,8,,CMO:0003442,retinal outer nuclear layer photoreceptor nucleus count to layer length ratio,,,,2.7,/ 100 um,2.0,5.6569,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,experimental eye,NRT,161,days,nondamaging retinal laser therapy (50 um) (for 0 hours),109069,nondamaging retinal laser therapy (50 um) (for 0 hours),,,,,,,, 3082,"Kang S, et al., Transl Vis Sci Technol. 2019 Aug 7;8(4):19. doi: 10.1167/tvst.8.4.19. eCollection 2019 Jul.",retinal photoreceptor quantity,,RS:0000655,RCS-p+/LavRrrc,not specified,180 days,8,,CMO:0003442,retinal outer nuclear layer photoreceptor nucleus count to layer length ratio,,,,3.3,/ 100 um,2.8,7.9196,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,109122,control condition,,,,,,,, 3082,"Kang S, et al., Transl Vis Sci Technol. 2019 Aug 7;8(4):19. doi: 10.1167/tvst.8.4.19. eCollection 2019 Jul.",retinal photoreceptor quantity,,RS:0000655,RCS-p+/LavRrrc,not specified,180 days,5,,CMO:0003442,retinal outer nuclear layer photoreceptor nucleus count to layer length ratio,,,,17.2,/ 100 um,5.4,12.0748,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,experimental eye,photocoagulation,161,days,laser photocoagulation (22.5 um) (for 0 hours),107361,laser photocoagulation (22.5 um) (for 0 hours),,,,,,,, 3082,"Kang S, et al., Transl Vis Sci Technol. 2019 Aug 7;8(4):19. doi: 10.1167/tvst.8.4.19. eCollection 2019 Jul.",retinal photoreceptor quantity,,RS:0000655,RCS-p+/LavRrrc,not specified,180 days,5,,CMO:0003442,retinal outer nuclear layer photoreceptor nucleus count to layer length ratio,,,,3.3,/ 100 um,2.8,6.261,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,contralateral control eye,,,,control condition,107362,control condition,,,,,,,, 3082,"Kang S, et al., Transl Vis Sci Technol. 2019 Aug 7;8(4):19. doi: 10.1167/tvst.8.4.19. eCollection 2019 Jul.",retinal photoreceptor quantity,,RS:0000655,RCS-p+/LavRrrc,not specified,180 days,5,,CMO:0003442,retinal outer nuclear layer photoreceptor nucleus count to layer length ratio,,,,16.2,/ 100 um,5.5,12.2984,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,experimental eye,photocoagulation,161,days,laser photocoagulation (45 um) (for 0 hours),107363,laser photocoagulation (45 um) (for 0 hours),,,,,,,, 3082,"Kang S, et al., Transl Vis Sci Technol. 2019 Aug 7;8(4):19. doi: 10.1167/tvst.8.4.19. eCollection 2019 Jul.",retinal photoreceptor quantity,,RS:0000655,RCS-p+/LavRrrc,not specified,180 days,5,,CMO:0003442,retinal outer nuclear layer photoreceptor nucleus count to layer length ratio,,,,2.4,/ 100 um,3.2,7.1554,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,contralateral control eye,,,,control condition,107364,control condition,,,,,,,, 3082,"Kang S, et al., Transl Vis Sci Technol. 2019 Aug 7;8(4):19. doi: 10.1167/tvst.8.4.19. eCollection 2019 Jul.",retinal photoreceptor quantity,,RS:0000655,RCS-p+/LavRrrc,not specified,180 days,5,,CMO:0003442,retinal outer nuclear layer photoreceptor nucleus count to layer length ratio,,,,30.8,/ 100 um,14.3,31.9758,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,experimental eye,photocoagulation,161,days,laser photocoagulation (67.5 um) (for 0 hours),107365,laser photocoagulation (67.5 um) (for 0 hours),,,,,,,, 3082,"Kang S, et al., Transl Vis Sci Technol. 2019 Aug 7;8(4):19. doi: 10.1167/tvst.8.4.19. eCollection 2019 Jul.",retinal photoreceptor quantity,,RS:0000655,RCS-p+/LavRrrc,not specified,180 days,5,,CMO:0003442,retinal outer nuclear layer photoreceptor nucleus count to layer length ratio,,,,3.4,/ 100 um,3.7,8.2735,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,contralateral control eye,,,,control condition,107366,control condition,,,,,,,, 3082,"Kang S, et al., Transl Vis Sci Technol. 2019 Aug 7;8(4):19. doi: 10.1167/tvst.8.4.19. eCollection 2019 Jul.",retinal photoreceptor quantity,,RS:0000655,RCS-p+/LavRrrc,not specified,180 days,5,,CMO:0003442,retinal outer nuclear layer photoreceptor nucleus count to layer length ratio,,,,3.1,/ 100 um,2.3,5.143,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,experimental eye,photocoagulation,161,days,laser photocoagulation (135 um) (for 0 hours),107367,laser photocoagulation (135 um) (for 0 hours),,,,,,,, 3082,"Kang S, et al., Transl Vis Sci Technol. 2019 Aug 7;8(4):19. doi: 10.1167/tvst.8.4.19. eCollection 2019 Jul.",retinal photoreceptor quantity,,RS:0000655,RCS-p+/LavRrrc,not specified,180 days,5,,CMO:0003442,retinal outer nuclear layer photoreceptor nucleus count to layer length ratio,,,,2.9,/ 100 um,3.0,6.7082,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,contralateral control eye,,,,control condition,107368,control condition,,,,,,,, 3082,"Kang S, et al., Transl Vis Sci Technol. 2019 Aug 7;8(4):19. doi: 10.1167/tvst.8.4.19. eCollection 2019 Jul.",retinal photoreceptor quantity,,RS:0000655,RCS-p+/LavRrrc,not specified,180 days,5,,CMO:0003442,retinal outer nuclear layer photoreceptor nucleus count to layer length ratio,,,,2.5,/ 100 um,1.5,3.3541,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,experimental eye,photocoagulation,161,days,laser photocoagulation (180 um) (for 0 hours),107369,laser photocoagulation (180 um) (for 0 hours),,,,,,,, 3082,"Kang S, et al., Transl Vis Sci Technol. 2019 Aug 7;8(4):19. doi: 10.1167/tvst.8.4.19. eCollection 2019 Jul.",retinal photoreceptor quantity,,RS:0000655,RCS-p+/LavRrrc,not specified,180 days,5,,CMO:0003442,retinal outer nuclear layer photoreceptor nucleus count to layer length ratio,,,,3.5,/ 100 um,3.0,6.7082,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,contralateral control eye,,,,control condition,107370,control condition,,,,,,,, 3082,"Kang S, et al., Transl Vis Sci Technol. 2019 Aug 7;8(4):19. doi: 10.1167/tvst.8.4.19. eCollection 2019 Jul.",retinal photoreceptor quantity,,RS:0000655,RCS-p+/LavRrrc,not specified,180 days,5,,CMO:0003442,retinal outer nuclear layer photoreceptor nucleus count to layer length ratio,,,,2.1,/ 100 um,1.9,4.2485,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,experimental eye,photocoagulation,161,days,laser photocoagulation (225 um) (for 0 hours),107371,laser photocoagulation (225 um) (for 0 hours),,,,,,,, 3082,"Kang S, et al., Transl Vis Sci Technol. 2019 Aug 7;8(4):19. doi: 10.1167/tvst.8.4.19. eCollection 2019 Jul.",retinal photoreceptor quantity,,RS:0000655,RCS-p+/LavRrrc,not specified,180 days,5,,CMO:0003442,retinal outer nuclear layer photoreceptor nucleus count to layer length ratio,,,,1.8,/ 100 um,1.9,4.2485,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,contralateral control eye,,,,control condition,107372,control condition,,,,,,,, 3137,"Hackbarth H, etal., Ren Physiol. 1983;6(2):63-71. doi: 10.1159/000172882.",kidney cortex morphology trait,,RS:0004778,MWF/Ztm,male,45 days,5,,CMO:0003670,renal cortex thickness,,,,2.25,mm,0.0537,0.12,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,109333,control condition,,,,,,,, 3137,"Hackbarth H, etal., Ren Physiol. 1983;6(2):63-71. doi: 10.1159/000172882.",kidney cortex morphology trait,,RS:0004778,MWF/Ztm,male,60 days,5,,CMO:0003670,renal cortex thickness,,,,2.63,mm,0.0492,0.11,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,109334,control condition,,,,,,,, 3137,"Hackbarth H, etal., Ren Physiol. 1983;6(2):63-71. doi: 10.1159/000172882.",kidney cortex morphology trait,,RS:0004778,MWF/Ztm,male,100 days,5,,CMO:0003670,renal cortex thickness,,,,2.63,mm,0.0581,0.13,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,109335,control condition,,,,,,,, 3137,"Hackbarth H, etal., Ren Physiol. 1983;6(2):63-71. doi: 10.1159/000172882.",kidney cortex morphology trait,,RS:0004778,MWF/Ztm,male,150 days,5,,CMO:0003670,renal cortex thickness,,,,2.89,mm,1.2924,2.89,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,109336,control condition,,,,,,,, 3137,"Hackbarth H, etal., Ren Physiol. 1983;6(2):63-71. doi: 10.1159/000172882.",kidney cortex morphology trait,,RS:0000533,LEW/Ztm,male,10 days,5,,CMO:0003670,renal cortex thickness,,,,0.65,mm,0.0224,0.05,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,109337,control condition,,,,,,,, 3137,"Hackbarth H, etal., Ren Physiol. 1983;6(2):63-71. doi: 10.1159/000172882.",kidney cortex morphology trait,,RS:0000533,LEW/Ztm,male,20 days,5,,CMO:0003670,renal cortex thickness,,,,1,mm,0.0358,0.08,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,109338,control condition,,,,,,,, 3137,"Hackbarth H, etal., Ren Physiol. 1983;6(2):63-71. doi: 10.1159/000172882.",kidney cortex morphology trait,,RS:0000533,LEW/Ztm,male,45 days,5,,CMO:0003670,renal cortex thickness,,,,2.34,mm,0.0716,0.16,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,109339,control condition,,,,,,,, 3137,"Hackbarth H, etal., Ren Physiol. 1983;6(2):63-71. doi: 10.1159/000172882.",kidney cortex morphology trait,,RS:0000533,LEW/Ztm,male,60 days,5,,CMO:0003670,renal cortex thickness,,,,2.73,mm,0.0581,0.13,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,109340,control condition,,,,,,,, 3137,"Hackbarth H, etal., Ren Physiol. 1983;6(2):63-71. doi: 10.1159/000172882.",kidney cortex morphology trait,,RS:0000533,LEW/Ztm,male,100 days,5,,CMO:0003670,renal cortex thickness,,,,2.75,mm,0.0492,0.11,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,109341,control condition,,,,,,,, 3137,"Hackbarth H, etal., Ren Physiol. 1983;6(2):63-71. doi: 10.1159/000172882.",kidney cortex morphology trait,,RS:0000533,LEW/Ztm,male,150 days,5,,CMO:0003670,renal cortex thickness,,,,2.96,mm,0.0894,0.2,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,109342,control condition,,,,,,,, 3137,"Hackbarth H, etal., Ren Physiol. 1983;6(2):63-71. doi: 10.1159/000172882.",kidney glomerulus size trait,,RS:0004778,MWF/Ztm,male,10 days,5,,CMO:0001166,kidney glomerulus diameter,,,,52.7,um,1.2522,2.8,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,109355,control condition,,,,,,,, 3137,"Hackbarth H, etal., Ren Physiol. 1983;6(2):63-71. doi: 10.1159/000172882.",kidney glomerulus size trait,,RS:0004778,MWF/Ztm,male,20 days,5,,CMO:0001166,kidney glomerulus diameter,,,,62.5,um,0.9839,2.2,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,109356,control condition,,,,,,,, 3137,"Hackbarth H, etal., Ren Physiol. 1983;6(2):63-71. doi: 10.1159/000172882.",kidney glomerulus size trait,,RS:0004778,MWF/Ztm,male,45 days,5,,CMO:0001166,kidney glomerulus diameter,,,,105,um,2.1466,4.8,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,109357,control condition,,,,,,,, 3137,"Hackbarth H, etal., Ren Physiol. 1983;6(2):63-71. doi: 10.1159/000172882.",kidney glomerulus size trait,,RS:0004778,MWF/Ztm,male,60 days,5,,CMO:0001166,kidney glomerulus diameter,,,,129.8,um,2.8622,6.4,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,109358,control condition,,,,,,,, 3137,"Hackbarth H, etal., Ren Physiol. 1983;6(2):63-71. doi: 10.1159/000172882.",kidney glomerulus size trait,,RS:0004778,MWF/Ztm,male,100 days,5,,CMO:0001166,kidney glomerulus diameter,,,,131.9,um,2.2361,5.0,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,109359,control condition,,,,,,,, 3137,"Hackbarth H, etal., Ren Physiol. 1983;6(2):63-71. doi: 10.1159/000172882.",kidney glomerulus size trait,,RS:0004778,MWF/Ztm,male,150 days,5,,CMO:0001166,kidney glomerulus diameter,,,,147.8,um,3.9355,8.8,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,109360,control condition,,,,,,,, 3137,"Hackbarth H, etal., Ren Physiol. 1983;6(2):63-71. doi: 10.1159/000172882.",kidney glomerulus size trait,,RS:0000533,LEW/Ztm,male,10 days,5,,CMO:0001166,kidney glomerulus diameter,,,,51.1,um,1.3416,3.0,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,109361,control condition,,,,,,,, 3137,"Hackbarth H, etal., Ren Physiol. 1983;6(2):63-71. doi: 10.1159/000172882.",kidney glomerulus size trait,,RS:0000533,LEW/Ztm,male,20 days,5,,CMO:0001166,kidney glomerulus diameter,,,,60.7,um,1.3416,3.0,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,109362,control condition,,,,,,,, 3137,"Hackbarth H, etal., Ren Physiol. 1983;6(2):63-71. doi: 10.1159/000172882.",kidney glomerulus size trait,,RS:0000533,LEW/Ztm,male,45 days,5,,CMO:0001166,kidney glomerulus diameter,,,,102.8,um,1.923,4.3,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,109363,control condition,,,,,,,, 3137,"Hackbarth H, etal., Ren Physiol. 1983;6(2):63-71. doi: 10.1159/000172882.",kidney glomerulus size trait,,RS:0000533,LEW/Ztm,male,60 days,5,,CMO:0001166,kidney glomerulus diameter,,,,115.3,um,2.1913,4.9,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,109364,control condition,,,,,,,, 3137,"Hackbarth H, etal., Ren Physiol. 1983;6(2):63-71. doi: 10.1159/000172882.",kidney glomerulus size trait,,RS:0000533,LEW/Ztm,male,100 days,5,,CMO:0001166,kidney glomerulus diameter,,,,118.2,um,1.5205,3.4,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,109365,control condition,,,,,,,, 3137,"Hackbarth H, etal., Ren Physiol. 1983;6(2):63-71. doi: 10.1159/000172882.",kidney glomerulus size trait,,RS:0000533,LEW/Ztm,male,150 days,5,,CMO:0001166,kidney glomerulus diameter,,,,131.4,um,2.2361,5.0,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,109366,control condition,,,,,,,, 3137,"Hackbarth H, etal., Ren Physiol. 1983;6(2):63-71. doi: 10.1159/000172882.",kidney cortex morphology trait,,RS:0004778,MWF/Ztm,male,10 days,5,,CMO:0003670,renal cortex thickness,,,,0.64,mm,0.0224,0.05,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,109330,control condition,,,,,,,, 3137,"Hackbarth H, etal., Ren Physiol. 1983;6(2):63-71. doi: 10.1159/000172882.",kidney cortex morphology trait,,RS:0004778,MWF/Ztm,male,20 days,5,,CMO:0003670,renal cortex thickness,,,,0.97,mm,0.0447,0.1,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,109331,control condition,,,,,,,, 3158,"Remuzzi A, etal., Kidney Int. 2006 Apr;69(7):1124-30. doi: 10.1038/sj.ki.5000060.",kidney glomerulus integrity trait,,RS:0004778,MWF/Ztm,male,420 days,9,,CMO:0003865,healthy glomeruli to total glomeruli ratio,,healthy glomeruli to total glomeruli ratio (CMO:0003865),,23,%,,,MMO:0000561,ex vivo light microscopy with histochemistry,glomerular capillary,0.0,,,,,controlled lisinopril content drinking water (80 mg/l) (for 70 days),110985,controlled lisinopril content drinking water (80 mg/l) (for 70 days),,,,,,,, 3162,"Remuzzi A, etal., Am J Kidney Dis. 1999 Oct;34(4):626-32. doi: 10.1016/S0272-6386(99)70385-9.",kidney glomerulus integrity trait,,RS:0004778,MWF/Ztm,male,140 days,8,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,,median,2.2,%,,,MMO:0000561,ex vivo light microscopy with histochemistry,left kidney,0.0,,,,,standard diet,109985,standard diet,,,,,,,, 3162,"Remuzzi A, etal., Am J Kidney Dis. 1999 Oct;34(4):626-32. doi: 10.1016/S0272-6386(99)70385-9.",kidney glomerulus integrity trait,,RS:0004778,MWF/Ztm,male,210 days,10,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,,median,18.6,%,,,MMO:0000561,ex vivo light microscopy with histochemistry,left kidney,0.0,,,,,standard diet,109986,standard diet,,,,,,,, 3162,"Remuzzi A, etal., Am J Kidney Dis. 1999 Oct;34(4):626-32. doi: 10.1016/S0272-6386(99)70385-9.",kidney glomerulus integrity trait,,RS:0004778,MWF/Ztm,male,210 days,7,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,,median,2.6,%,,,MMO:0000561,ex vivo light microscopy with histochemistry,left kidney,0.0,,,,,controlled lisinopril content drinking water (50 mg/l) (for 70 days),109987,controlled lisinopril content drinking water (50 mg/l) (for 70 days),,,,,,,, 3197,"Ng B, etal., Ann Thorac Surg. 1995 Jan;59(1):205-8. doi: 10.1016/0003-4975(94)00774-2.",lung integrity trait,,RS:0004058,BDIX/HanHsd,female,0 days,5,,CMO:0003434,metastatic lung tumor number,,Group 3,,421,,25.9384,58.0,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,"India ink stain; tissue stains, tumors white",,26,days,DHD/K12/TRb - Sp-5 cells (1 X 10E6) then isolated lung perfusion with floxuridine (3.5 mg/ml) (for 0.3 hours),111183,DHD/K12/TRb - Sp-5 cells (1 X 10E6) ,,,isolated lung perfusion with floxuridine (3.5 mg/ml) (for 0.3 hours),,,,, 3197,"Ng B, etal., Ann Thorac Surg. 1995 Jan;59(1):205-8. doi: 10.1016/0003-4975(94)00774-2.",lung integrity trait,,RS:0004058,BDIX/HanHsd,female,0 days,7,,CMO:0003434,metastatic lung tumor number,,Group 4,,169,,13.2288,35.0,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,"India ink stain; tissue stains, tumors white",,26,days,DHD/K12/TRb - Sp-5 cells (1 X 10E6) then isolated lung perfusion with floxuridine (7 mg/ml) (for 0.3 hours),111184,DHD/K12/TRb - Sp-5 cells (1 X 10E6) ,,,isolated lung perfusion with floxuridine (7 mg/ml) (for 0.3 hours),,,,, 3197,"Ng B, etal., Ann Thorac Surg. 1995 Jan;59(1):205-8. doi: 10.1016/0003-4975(94)00774-2.",lung integrity trait,,RS:0004058,BDIX/HanHsd,female,0 days,7,,CMO:0003434,metastatic lung tumor number,,Group 5,,11,,2.2678,6.0,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,"India ink stain; tissue stains, tumors white",,26,days,DHD/K12/TRb - Sp-5 cells (1 X 10E6) then isolated lung perfusion with floxuridine (14 mg/ml) (for 0.3 hours),111185,DHD/K12/TRb - Sp-5 cells (1 X 10E6) ,,,isolated lung perfusion with floxuridine (14 mg/ml) (for 0.3 hours),,,,, 3197,"Ng B, etal., Ann Thorac Surg. 1995 Jan;59(1):205-8. doi: 10.1016/0003-4975(94)00774-2.",lung integrity trait,,RS:0004058,BDIX/HanHsd,female,0 days,4,,CMO:0003434,metastatic lung tumor number,,Group 2,,617,,37.0,74.0,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,"India ink stain; tissue stains, tumors white",,26,days,DHD/K12/TRb - Sp-5 cells (1 X 10E6) then isolated lung perfusion with Hespan buffer (1 ml/min) (for 0.3 hours),111177,DHD/K12/TRb - Sp-5 cells (1 X 10E6) ,,,isolated lung perfusion with Hespan buffer (1 ml/min) (for 0.3 hours),,,,, 3197,"Ng B, etal., Ann Thorac Surg. 1995 Jan;59(1):205-8. doi: 10.1016/0003-4975(94)00774-2.",lung integrity trait,,RS:0004058,BDIX/HanHsd,female,0 days,7,,CMO:0003434,metastatic lung tumor number,,Group 4,,490,,34.3948,91.0,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,"India ink stain; tissue stains, tumors white",,26,days,DHD/K12/TRb - Sp-5 cells (1 X 10E6) then isolated lung perfusion with floxuridine (7 mg/ml) (for 0.3 hours),111179,DHD/K12/TRb - Sp-5 cells (1 X 10E6) ,,,isolated lung perfusion with floxuridine (7 mg/ml) (for 0.3 hours),,,,, 3197,"Ng B, etal., Ann Thorac Surg. 1995 Jan;59(1):205-8. doi: 10.1016/0003-4975(94)00774-2.",lung integrity trait,,RS:0004058,BDIX/HanHsd,female,0 days,7,,CMO:0003434,metastatic lung tumor number,,Group 5,,455,,32.8829,87.0,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,"India ink stain; tissue stains, tumors white",,26,days,DHD/K12/TRb - Sp-5 cells (1 X 10E6) then isolated lung perfusion with floxuridine (14 mg/ml) (for 0.3 hours),111180,DHD/K12/TRb - Sp-5 cells (1 X 10E6) ,,,isolated lung perfusion with floxuridine (14 mg/ml) (for 0.3 hours),,,,, 3197,"Ng B, etal., Ann Thorac Surg. 1995 Jan;59(1):205-8. doi: 10.1016/0003-4975(94)00774-2.",lung integrity trait,,RS:0004058,BDIX/HanHsd,female,0 days,5,,CMO:0003434,metastatic lung tumor number,,Group 1,,216,,41.5909,93.0,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,"India ink stain; tissue stains, tumors white",,26,days,DHD/K12/TRb - Sp-5 cells (1 X 10E6) then floxuridine (1 mg/kg/d) (for 7 days),111181,DHD/K12/TRb - Sp-5 cells (1 X 10E6) ,,,floxuridine (1 mg/kg/d) (for 7 days),,,,, 3197,"Ng B, etal., Ann Thorac Surg. 1995 Jan;59(1):205-8. doi: 10.1016/0003-4975(94)00774-2.",lung integrity trait,,RS:0004058,BDIX/HanHsd,female,0 days,4,,CMO:0003434,metastatic lung tumor number,,Group 2,,503,,17.0,34.0,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,"India ink stain; tissue stains, tumors white",,26,days,DHD/K12/TRb - Sp-5 cells (1 X 10E6) then isolated lung perfusion with Hespan buffer (1 ml/min) (for 0.3 hours),111182,DHD/K12/TRb - Sp-5 cells (1 X 10E6) ,,,isolated lung perfusion with Hespan buffer (1 ml/min) (for 0.3 hours),,,,, 3197,"Ng B, etal., Ann Thorac Surg. 1995 Jan;59(1):205-8. doi: 10.1016/0003-4975(94)00774-2.",lung integrity trait,,RS:0004058,BDIX/HanHsd,female,0 days,5,,CMO:0003434,metastatic lung tumor number,,Group 1,,290,,47.8519,107.0,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,"India ink stain; tissue stains, tumors white",,26,days,DHD/K12/TRb - Sp-5 cells (1 X 10E6) then floxuridine (1 mg/kg/d) (for 7 days),111176,DHD/K12/TRb - Sp-5 cells (1 X 10E6) ,,,floxuridine (1 mg/kg/d) (for 7 days),,,,, 3197,"Ng B, etal., Ann Thorac Surg. 1995 Jan;59(1):205-8. doi: 10.1016/0003-4975(94)00774-2.",lung integrity trait,,RS:0004058,BDIX/HanHsd,female,0 days,5,,CMO:0003434,metastatic lung tumor number,,Group 3,,541,,39.3548,88.0,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,"India ink stain; tissue stains, tumors white",,26,days,DHD/K12/TRb - Sp-5 cells (1 X 10E6) then isolated lung perfusion with floxuridine (3.5 mg/ml) (for 0.3 hours),111178,DHD/K12/TRb - Sp-5 cells (1 X 10E6) ,,,isolated lung perfusion with floxuridine (3.5 mg/ml) (for 0.3 hours),,,,, 3195,"Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x.",liver integrity trait,,RS:0001792,BDIX/OrlCrl,male,0 days,5,,CMO:0003613,number of large metastatic liver tumors,,group B,,0,,0.0,0.0,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,30,days,DHD/K12/TRb cells (2 X 10E6) ,111159,DHD/K12/TRb cells (2 X 10E6) ,,,,,,,, 3195,"Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x.",liver integrity trait,,RS:0001792,BDIX/OrlCrl,male,0 days,5,,CMO:0003613,number of large metastatic liver tumors,,group 2,,1,,0.0,0.0,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,30,days,DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (1 X 10E6) ,111162,DHD/K12/TRb cells (1 X 10E6) ,DHD/K12/TRb cells (1 X 10E6) ,,,,,,, 3195,"Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x.",liver integrity trait,,RS:0001792,BDIX/OrlCrl,male,0 days,5,,CMO:0003613,number of large metastatic liver tumors,,group 3,,1,,0.0,0.0,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,30,days,DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (1.5 X 10E6) ,111163,DHD/K12/TRb cells (1 X 10E6) ,DHD/K12/TRb cells (1.5 X 10E6) ,,,,,,, 3195,"Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x.",liver integrity trait,,RS:0001792,BDIX/OrlCrl,male,0 days,5,,CMO:0003782,number of large metastatic liver tumors in the right liver,,group 1,,0,,0.0,0.0,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,30,days,DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (0.5 X 10E6) ,111167,DHD/K12/TRb cells (1 X 10E6) ,DHD/K12/TRb cells (0.5 X 10E6) ,,,,,,, 3195,"Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x.",liver integrity trait,,RS:0001792,BDIX/OrlCrl,male,0 days,5,,CMO:0003781,number of large metastatic liver tumors in the left liver,,group A,,0,,0.0,0.0,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,30,days,DHD/K12/TRb cells (1 X 10E6) ,111170,DHD/K12/TRb cells (1 X 10E6) ,,,,,,,, 3195,"Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x.",liver integrity trait,,RS:0001792,BDIX/OrlCrl,male,0 days,5,,CMO:0003781,number of large metastatic liver tumors in the left liver,,group 3,,1,,0.0,0.0,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,30,days,DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (1.5 X 10E6) ,111175,DHD/K12/TRb cells (1 X 10E6) ,DHD/K12/TRb cells (1.5 X 10E6) ,,,,,,, 3195,"Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x.",liver integrity trait,,RS:0001792,BDIX/OrlCrl,male,0 days,5,,CMO:0003613,number of large metastatic liver tumors,,group A,,0,,0.0,0.0,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,30,days,DHD/K12/TRb cells (1 X 10E6) ,111158,DHD/K12/TRb cells (1 X 10E6) ,,,,,,,, 3195,"Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x.",liver integrity trait,,RS:0001792,BDIX/OrlCrl,male,0 days,5,,CMO:0003782,number of large metastatic liver tumors in the right liver,,group A,,0,,0.0,0.0,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,30,days,DHD/K12/TRb cells (1 X 10E6) ,111164,DHD/K12/TRb cells (1 X 10E6) ,,,,,,,, 3195,"Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x.",liver integrity trait,,RS:0001792,BDIX/OrlCrl,male,0 days,5,,CMO:0003782,number of large metastatic liver tumors in the right liver,,group B,,0,,0.0,0.0,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,30,days,DHD/K12/TRb cells (2 X 10E6) ,111165,DHD/K12/TRb cells (2 X 10E6) ,,,,,,,, 3195,"Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x.",liver integrity trait,,RS:0001792,BDIX/OrlCrl,male,0 days,5,,CMO:0003782,number of large metastatic liver tumors in the right liver,,group C,,0,,0.0,0.0,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,30,days,DHD/K12/TRb cells (3 X 10E6) ,111166,DHD/K12/TRb cells (3 X 10E6) ,,,,,,,, 3195,"Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x.",liver integrity trait,,RS:0001792,BDIX/OrlCrl,male,0 days,5,,CMO:0003782,number of large metastatic liver tumors in the right liver,,group 2,,0,,0.0,0.0,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,30,days,DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (1 X 10E6) ,111168,DHD/K12/TRb cells (1 X 10E6) ,DHD/K12/TRb cells (1 X 10E6) ,,,,,,, 3195,"Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x.",liver integrity trait,,RS:0001792,BDIX/OrlCrl,male,0 days,5,,CMO:0003781,number of large metastatic liver tumors in the left liver,,group B,,0,,0.0,0.0,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,30,days,DHD/K12/TRb cells (2 X 10E6) ,111171,DHD/K12/TRb cells (2 X 10E6) ,,,,,,,, 3195,"Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x.",liver integrity trait,,RS:0001792,BDIX/OrlCrl,male,0 days,5,,CMO:0003781,number of large metastatic liver tumors in the left liver,,group C,,0,,0.0,0.0,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,30,days,DHD/K12/TRb cells (3 X 10E6) ,111172,DHD/K12/TRb cells (3 X 10E6) ,,,,,,,, 3195,"Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x.",liver integrity trait,,RS:0001792,BDIX/OrlCrl,male,0 days,5,,CMO:0003781,number of large metastatic liver tumors in the left liver,,group 1,,1,,0.0,0.0,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,30,days,DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (0.5 X 10E6) ,111173,DHD/K12/TRb cells (1 X 10E6) ,DHD/K12/TRb cells (0.5 X 10E6) ,,,,,,, 3195,"Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x.",liver integrity trait,,RS:0001792,BDIX/OrlCrl,male,0 days,5,,CMO:0003777,small liver metastatic tumorous lesion diameter measurement,,group A,,0.8,mm,0.1789,0.4,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,30,days,DHD/K12/TRb cells (1 X 10E6) ,111077,DHD/K12/TRb cells (1 X 10E6) ,,,,,,,, 3195,"Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x.",liver integrity trait,,RS:0001792,BDIX/OrlCrl,male,0 days,5,,CMO:0003777,small liver metastatic tumorous lesion diameter measurement,,group C,,1.8,mm,0.4472,1.0,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,30,days,DHD/K12/TRb cells (3 X 10E6) ,111079,DHD/K12/TRb cells (3 X 10E6) ,,,,,,,, 3195,"Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x.",liver integrity trait,,RS:0001792,BDIX/OrlCrl,male,0 days,5,,CMO:0003777,small liver metastatic tumorous lesion diameter measurement,,group 1,,0.8,mm,0.2236,0.5,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,30,days,DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (0.5 X 10E6) ,111080,DHD/K12/TRb cells (1 X 10E6) ,DHD/K12/TRb cells (0.5 X 10E6) ,,,,,,, 3195,"Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x.",liver integrity trait,,RS:0001792,BDIX/OrlCrl,male,0 days,5,,CMO:0003777,small liver metastatic tumorous lesion diameter measurement,,group 2,,0.9,mm,0.2236,0.5,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,30,days,DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (1 X 10E6) ,111081,DHD/K12/TRb cells (1 X 10E6) ,DHD/K12/TRb cells (1 X 10E6) ,,,,,,, 3195,"Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x.",liver integrity trait,,RS:0001792,BDIX/OrlCrl,male,0 days,5,,CMO:0003777,small liver metastatic tumorous lesion diameter measurement,,group 3,,0.8,mm,0.1789,0.4,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,30,days,DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (1.5 X 10E6) ,111082,DHD/K12/TRb cells (1 X 10E6) ,DHD/K12/TRb cells (1.5 X 10E6) ,,,,,,, 3195,"Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x.",liver integrity trait,,RS:0001792,BDIX/OrlCrl,male,0 days,5,,CMO:0003777,small liver metastatic tumorous lesion diameter measurement,,group B,,1.2,mm,0.313,0.7,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,30,days,DHD/K12/TRb cells (2 X 10E6) ,111078,DHD/K12/TRb cells (2 X 10E6) ,,,,,,,, 3195,"Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x.",liver integrity trait,,RS:0001792,BDIX/OrlCrl,male,0 days,5,,CMO:0003778,large liver metastatic tumorous lesion diameter measurement,,group 1,,7.9,mm,0.4472,1.0,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,30,days,DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (0.5 X 10E6) ,111083,DHD/K12/TRb cells (1 X 10E6) ,DHD/K12/TRb cells (0.5 X 10E6) ,,,,,,, 3195,"Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x.",liver integrity trait,,RS:0001792,BDIX/OrlCrl,male,0 days,5,,CMO:0003778,large liver metastatic tumorous lesion diameter measurement,,group 2,,10.1,mm,0.0268,0.06,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,30,days,DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (1 X 10E6) ,111084,DHD/K12/TRb cells (1 X 10E6) ,DHD/K12/TRb cells (1 X 10E6) ,,,,,,, 3195,"Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x.",liver integrity trait,,RS:0001792,BDIX/OrlCrl,male,0 days,5,,CMO:0003778,large liver metastatic tumorous lesion diameter measurement,,group 3,,17.7,mm,0.3578,0.8,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,30,days,DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (1.5 X 10E6) ,111085,DHD/K12/TRb cells (1 X 10E6) ,DHD/K12/TRb cells (1.5 X 10E6) ,,,,,,, 3195,"Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x.",liver integrity trait,,RS:0001792,BDIX/OrlCrl,male,0 days,3,,CMO:0003611,number of small metastatic liver tumors,,sham surgical group,,0,,0.0,0.0,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,30,days,phosphate buffered saline (0.2 ml) then phosphate buffered saline (0.1 ml) ,111057,phosphate buffered saline (0.2 ml) ,,,phosphate buffered saline (0.1 ml) ,,,,, 3195,"Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x.",liver integrity trait,,RS:0001792,BDIX/OrlCrl,male,0 days,5,,CMO:0003611,number of small metastatic liver tumors,,group A,,12,,0.8944,2.0,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,30,days,DHD/K12/TRb cells (1 X 10E6) ,111058,DHD/K12/TRb cells (1 X 10E6) ,,,,,,,, 3195,"Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x.",liver integrity trait,,RS:0001792,BDIX/OrlCrl,male,0 days,5,,CMO:0003611,number of small metastatic liver tumors,,group B,,17,,0.8944,2.0,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,30,days,DHD/K12/TRb cells (2 X 10E6) ,111059,DHD/K12/TRb cells (2 X 10E6) ,,,,,,,, 3195,"Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x.",liver integrity trait,,RS:0001792,BDIX/OrlCrl,male,0 days,5,,CMO:0003611,number of small metastatic liver tumors,,group C,,22,,0.8944,2.0,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,30,days,DHD/K12/TRb cells (3 X 10E6) ,111060,DHD/K12/TRb cells (3 X 10E6) ,,,,,,,, 3195,"Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x.",liver integrity trait,,RS:0001792,BDIX/OrlCrl,male,0 days,5,,CMO:0003611,number of small metastatic liver tumors,,group 1,,11,,0.4472,1.0,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,30,days,DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (0.5 X 10E6) ,111061,DHD/K12/TRb cells (1 X 10E6) ,DHD/K12/TRb cells (0.5 X 10E6) ,,,,,,, 3195,"Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x.",liver integrity trait,,RS:0001792,BDIX/OrlCrl,male,0 days,5,,CMO:0003611,number of small metastatic liver tumors,,group 2,,12,,1.3416,3.0,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,30,days,DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (1 X 10E6) ,111062,DHD/K12/TRb cells (1 X 10E6) ,DHD/K12/TRb cells (1 X 10E6) ,,,,,,, 3195,"Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x.",liver integrity trait,,RS:0001792,BDIX/OrlCrl,male,0 days,5,,CMO:0003611,number of small metastatic liver tumors,,group 3,,10,,0.4472,1.0,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,30,days,DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (1.5 X 10E6) ,111063,DHD/K12/TRb cells (1 X 10E6) ,DHD/K12/TRb cells (1.5 X 10E6) ,,,,,,, 3195,"Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x.",liver integrity trait,,RS:0001792,BDIX/OrlCrl,male,0 days,5,,CMO:0003613,number of large metastatic liver tumors,,group C,,0,,0.0,0.0,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,30,days,DHD/K12/TRb cells (3 X 10E6) ,111160,DHD/K12/TRb cells (3 X 10E6) ,,,,,,,, 3195,"Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x.",liver integrity trait,,RS:0001792,BDIX/OrlCrl,male,0 days,5,,CMO:0003613,number of large metastatic liver tumors,,group 1,,1,,0.0,0.0,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,30,days,DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (0.5 X 10E6) ,111161,DHD/K12/TRb cells (1 X 10E6) ,DHD/K12/TRb cells (0.5 X 10E6) ,,,,,,, 3195,"Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x.",liver integrity trait,,RS:0001792,BDIX/OrlCrl,male,0 days,5,,CMO:0003782,number of large metastatic liver tumors in the right liver,,group 3,,0,,0.0,0.0,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,30,days,DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (1.5 X 10E6) ,111169,DHD/K12/TRb cells (1 X 10E6) ,DHD/K12/TRb cells (1.5 X 10E6) ,,,,,,, 3195,"Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x.",liver integrity trait,,RS:0001792,BDIX/OrlCrl,male,0 days,5,,CMO:0003781,number of large metastatic liver tumors in the left liver,,group 2,,1,,0.0,0.0,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,30,days,DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (1 X 10E6) ,111174,DHD/K12/TRb cells (1 X 10E6) ,DHD/K12/TRb cells (1 X 10E6) ,,,,,,, 3088,"Wong VY, etal., Br J Pharmacol. 2001 Nov;134(5):977-84. doi: 10.1038/sj.bjp.0704329.",kidney integrity trait,,RS:0000714,WKY/N,male,224 days to 210 days,N/A,,CMO:0003443,kidney tubule regeneration foci count,,foci of tubular regeneration,,0.5,/section,0.4,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,107483,control condition,,,,,,,, 3088,"Wong VY, etal., Br J Pharmacol. 2001 Nov;134(5):977-84. doi: 10.1038/sj.bjp.0704329.",kidney integrity trait,,RS:0000775,SHRSP/A3N,male,224 days to 210 days,N/A,,CMO:0003443,kidney tubule regeneration foci count,,foci of tubular regeneration,,5.8,/section,1.8,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,107484,control condition,,,,,,,, 3088,"Wong VY, etal., Br J Pharmacol. 2001 Nov;134(5):977-84. doi: 10.1038/sj.bjp.0704329.",kidney integrity trait,,RS:0000775,SHRSP/A3N,male,224 days to 210 days,N/A,,CMO:0003443,kidney tubule regeneration foci count,,foci of tubular regeneration,,6.4,/section,1.0,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,controlled sodium content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days),107485,controlled sodium content drinking water (1 %) (for 126 days),controlled fat content diet (24.5 %) (for 126 days),,,,,,, 3088,"Wong VY, etal., Br J Pharmacol. 2001 Nov;134(5):977-84. doi: 10.1038/sj.bjp.0704329.",kidney integrity trait,,RS:0000775,SHRSP/A3N,male,224 days to 210 days,N/A,,CMO:0003443,kidney tubule regeneration foci count,,foci of tubular regeneration,,1.9,/section,1.3,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,controlled sodium content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) and controlled carvedilol content diet (2400 ppm) (for 126 days),107486,controlled sodium content drinking water (1 %) (for 126 days),controlled fat content diet (24.5 %) (for 126 days),controlled carvedilol content diet (2400 ppm) (for 126 days),,,,,, 3088,"Wong VY, etal., Br J Pharmacol. 2001 Nov;134(5):977-84. doi: 10.1038/sj.bjp.0704329.",kidney integrity trait,,RS:0000714,WKY/N,male,224 days to 210 days,N/A,,CMO:0003445,interstitial nephritis foci count,,foci of interstitial nephritis,,0.9,/section,0.4,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,107487,control condition,,,,,,,, 3088,"Wong VY, etal., Br J Pharmacol. 2001 Nov;134(5):977-84. doi: 10.1038/sj.bjp.0704329.",kidney integrity trait,,RS:0000775,SHRSP/A3N,male,224 days to 210 days,N/A,,CMO:0003445,interstitial nephritis foci count,,foci of interstitial nephritis,,3.1,/section,0.7,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,107488,control condition,,,,,,,, 3088,"Wong VY, etal., Br J Pharmacol. 2001 Nov;134(5):977-84. doi: 10.1038/sj.bjp.0704329.",kidney integrity trait,,RS:0000775,SHRSP/A3N,male,224 days to 210 days,N/A,,CMO:0003445,interstitial nephritis foci count,,foci of interstitial nephritis,,6.6,/section,2.3,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,controlled sodium content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days),107489,controlled sodium content drinking water (1 %) (for 126 days),controlled fat content diet (24.5 %) (for 126 days),,,,,,, 3088,"Wong VY, etal., Br J Pharmacol. 2001 Nov;134(5):977-84. doi: 10.1038/sj.bjp.0704329.",kidney integrity trait,,RS:0000775,SHRSP/A3N,male,224 days to 210 days,N/A,,CMO:0003445,interstitial nephritis foci count,,foci of interstitial nephritis,,2.4,/section,0.8,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,controlled sodium content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) and controlled carvedilol content diet (2400 ppm) (for 126 days),107490,controlled sodium content drinking water (1 %) (for 126 days),controlled fat content diet (24.5 %) (for 126 days),controlled carvedilol content diet (2400 ppm) (for 126 days),,,,,, 3088,"Wong VY, etal., Br J Pharmacol. 2001 Nov;134(5):977-84. doi: 10.1038/sj.bjp.0704329.",kidney integrity trait,,RS:0000714,WKY/N,male,224 days to 210 days,N/A,,CMO:0003444,kidney total tubule cast count,,total tubular casts,,0.6,/section,0.3,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,107491,control condition,,,,,,,, 3088,"Wong VY, etal., Br J Pharmacol. 2001 Nov;134(5):977-84. doi: 10.1038/sj.bjp.0704329.",kidney integrity trait,,RS:0000775,SHRSP/A3N,male,224 days to 210 days,N/A,,CMO:0003444,kidney total tubule cast count,,total tubular casts,,72,/section,18.0,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,107492,control condition,,,,,,,, 3088,"Wong VY, etal., Br J Pharmacol. 2001 Nov;134(5):977-84. doi: 10.1038/sj.bjp.0704329.",kidney integrity trait,,RS:0000775,SHRSP/A3N,male,224 days to 210 days,N/A,,CMO:0003444,kidney total tubule cast count,,total tubular casts,,350,/section,80.0,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,controlled sodium content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days),107493,controlled sodium content drinking water (1 %) (for 126 days),controlled fat content diet (24.5 %) (for 126 days),,,,,,, 3088,"Wong VY, etal., Br J Pharmacol. 2001 Nov;134(5):977-84. doi: 10.1038/sj.bjp.0704329.",kidney integrity trait,,RS:0000775,SHRSP/A3N,male,224 days to 210 days,N/A,,CMO:0003444,kidney total tubule cast count,,total tubular casts,,21,/section,11.0,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,controlled sodium content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) and controlled carvedilol content diet (2400 ppm) (for 126 days),107494,controlled sodium content drinking water (1 %) (for 126 days),controlled fat content diet (24.5 %) (for 126 days),controlled carvedilol content diet (2400 ppm) (for 126 days),,,,,, 3088,"Wong VY, etal., Br J Pharmacol. 2001 Nov;134(5):977-84. doi: 10.1038/sj.bjp.0704329.",kidney integrity trait,,RS:0000714,WKY/N,male,224 days to 210 days,N/A,,CMO:0003446,renal fibrosis foci count,,foci of renal fibrosis,,16,/section,1.0,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,107495,control condition,,,,,,,, 3088,"Wong VY, etal., Br J Pharmacol. 2001 Nov;134(5):977-84. doi: 10.1038/sj.bjp.0704329.",kidney integrity trait,,RS:0000775,SHRSP/A3N,male,224 days to 210 days,N/A,,CMO:0003446,renal fibrosis foci count,,foci of renal fibrosis,,20,/section,2.0,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,107496,control condition,,,,,,,, 3088,"Wong VY, etal., Br J Pharmacol. 2001 Nov;134(5):977-84. doi: 10.1038/sj.bjp.0704329.",kidney integrity trait,,RS:0000775,SHRSP/A3N,male,224 days to 210 days,N/A,,CMO:0003446,renal fibrosis foci count,,foci of renal fibrosis,,25,/section,1.0,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,controlled sodium content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days),107497,controlled sodium content drinking water (1 %) (for 126 days),controlled fat content diet (24.5 %) (for 126 days),,,,,,, 3088,"Wong VY, etal., Br J Pharmacol. 2001 Nov;134(5):977-84. doi: 10.1038/sj.bjp.0704329.",kidney integrity trait,,RS:0000775,SHRSP/A3N,male,224 days to 210 days,N/A,,CMO:0003446,renal fibrosis foci count,,foci of renal fibrosis,,15,/section,2.0,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,controlled sodium content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) and controlled carvedilol content diet (2400 ppm) (for 126 days),107498,controlled sodium content drinking water (1 %) (for 126 days),controlled fat content diet (24.5 %) (for 126 days),controlled carvedilol content diet (2400 ppm) (for 126 days),,,,,, 3088,"Wong VY, etal., Br J Pharmacol. 2001 Nov;134(5):977-84. doi: 10.1038/sj.bjp.0704329.",kidney glomerulus integrity trait,,RS:0000714,WKY/N,male,224 days to 210 days,N/A,,CMO:0003447,kidney glomerular lesion count,,,,0.5,/section,0.4,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,107475,control condition,,,,,,,, 3088,"Wong VY, etal., Br J Pharmacol. 2001 Nov;134(5):977-84. doi: 10.1038/sj.bjp.0704329.",kidney glomerulus integrity trait,,RS:0000775,SHRSP/A3N,male,224 days to 210 days,N/A,,CMO:0003447,kidney glomerular lesion count,,,,6,/section,2.0,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,control condition,107476,control condition,,,,,,,, 3088,"Wong VY, etal., Br J Pharmacol. 2001 Nov;134(5):977-84. doi: 10.1038/sj.bjp.0704329.",kidney glomerulus integrity trait,,RS:0000775,SHRSP/A3N,male,224 days to 210 days,N/A,,CMO:0003447,kidney glomerular lesion count,,,,31,/section,5.0,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,controlled sodium content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days),107477,controlled sodium content drinking water (1 %) (for 126 days),controlled fat content diet (24.5 %) (for 126 days),,,,,,, 3088,"Wong VY, etal., Br J Pharmacol. 2001 Nov;134(5):977-84. doi: 10.1038/sj.bjp.0704329.",kidney glomerulus integrity trait,,RS:0000775,SHRSP/A3N,male,224 days to 210 days,N/A,,CMO:0003447,kidney glomerular lesion count,,,,4,/section,2.0,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,controlled sodium content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) and controlled carvedilol content diet (2400 ppm) (for 126 days),107478,controlled sodium content drinking water (1 %) (for 126 days),controlled fat content diet (24.5 %) (for 126 days),controlled carvedilol content diet (2400 ppm) (for 126 days),,,,,,